Randomised controlled trial of two-component, three-component, and five-component acellular pertussis vaccines compared with whole-cell pertussis vaccine

Olin, Patrick; Rasmussen, Finn; Gustafsson, Lennart; Hallander, Hans O.; Heijbel, Harald

doi:10.1016/s0140-6736(97)06508-2

Cited by 295 publications

(168 citation statements)

References 21 publications

Supporting

Mentioning

153

Contrasting

Unclassified

Order By: Relevance

“…17,28,32,33 Previous studies also demonstrated that most good WPVs had efficacy of 93-96% in children and a UK WPVs was significantly more protective than the 3-components purified APVs in a randomized controlled trial. [34][35][36] This has been attributed to the induction of Th1 cells by WPVs. 30 The mechanism of immunity against B. pertussis involves both humoral and cellular immune responses but not directed against a single protective antigen in an aerosol challenge model.…”

Section: Discussionmentioning

confidence: 99%

Characterization of co-purified acellular pertussis vaccines

Tan

Asokanathan

et al. 2015

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

These authors contributed equally to this work.Keyword: Co-purified acellular pertussis vaccines, immune responses, protection, proteomic analysis Abbreviations: WPVs, whole-cell pertussis vaccines; APVs, acellular pertussis vaccines; PT, pertussis toxin; FHA, filamentous hemagglutinin; 2-DE, 2-dimensional gel electrophoresis; PRN, pertactin; FIM, fimbriae; BipA, putative outer membrane ligand binding protein; Sbp, sulfate-binding protein precursor; sphB1, autotransporter subtilisin-like protease; bvg, Bordetella virulence regulon; SHD, single human doseWhole-cell pertussis vaccines (WPVs) have been completely replaced by the co-purified acellular vaccines (APVs) in China. To date few laboratory studies were reported for co-purified APVs in terms of their antigenic composition and protective immune responses. To further understand the antigenic composition in co-purified APVs, in the present study 2-dimensional gel electrophoresis-based proteomic technology was used to analyze the composition of copurified APVs. The results showed that besides the main antigens pertussis toxin (PT) and filamentous hemagglutinin (FHA), co-purified APVs also contained pertactin (PRN), fimbriae (FIM) 2and3 and other minor protein antigens. Of the 9 proteins identified, 3 were differentially presented in products from manufacturer 1 and manufacturer 2. Compared with WPVs and purified APVs, co-purified APVs induced a mixed Th1/Th2 immune response with more toward to a Th1 response than the purified APVs in this study. These results hint that different immune mechanisms might be involved in protection induced by co-purified and purified APVs.

show abstract

Section: Discussionmentioning

confidence: 99%

Characterization of co-purified acellular pertussis vaccines

Tan

Asokanathan

et al. 2015

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

show abstract

“…Indeed, the serosurvey demonstrates that the highest proportion of those <2 years of age seronegative for anti-PT amongst all countries was in The Netherlands, suggesting reduced protection against clinically typical infection in the Dutch population. Variation in vaccine effectiveness for locally produced vaccines (particularly whole-cell vaccine) has been reported [39][40][41].…”

Section: Role Of Svfmentioning

confidence: 99%

The seroepidemiology of Bordetella pertussis infection in Western Europe

Pebody¹,

GAY²,

et al. 2004

View full text Add to dashboard Cite

SUMMARYHigh titres of pertussis toxin (PT) antibody have been shown to be predictive of recent infection with Bordetella pertussis. The seroprevalence of standardized anti-PT antibody was determined in six Western European countries between 1994 and 1998 and related to historical surveillance and vaccine programme data. Standardized anti-PT titres were calculated for a series of whole-cell and acellular pertussis vaccine trials. For the serological surveys, high-titre sera (>125 units/ml) were distributed throughout all age groups in both high-(>90 %) and low-coverage (<90 %) countries. High-titre sera were more likely in infants in countries using high-titre-producing vaccines in their primary programme (Italy, 11 . 5% ; Western Germany, 13 . 3 % ; France, 4 . 3% ; Eastern Germany, 4 . 0%) compared to other countries (The Netherlands, 0 . 5 %; Finland, 0 %). Recent infection was significantly more likely in adolescents (10-19 years old) and adults in high-coverage countries (Finland, The Netherlands, France, East Germany), whereas infection was more likely in children (3-9 years old) than adolescents in low-coverage (<90% ; Italy, West Germany, United Kingdom) countries. The impact and role of programmatic changes introduced after these surveys aimed at protecting infants from severe disease by accelerating the primary schedule or vaccinating older children and adolescents with booster doses can be evaluated with this approach.

show abstract

“…In addition to Ptx, the ACVs may contain filamentous hemagglutinin (FHA), pertactin (Prn), and fimbriae (Fim). Although field trials have shown that ACVs are less reactogenic than WCVs (8, 11-14, 34, 35), only a single ACV, comprised of Ptx, Prn, Fim, and FHA, was shown to be as efficacious as a good WCV (19,26). Because of their lower reactogenicity, ACVs have replaced WCVs in most developed countries.…”

mentioning

confidence: 99%

Analysis of Bordetella pertussis Populations in European Countries with Different Vaccination Policies

et al. 2005

View full text Add to dashboard Cite

Despite the widespread use of pertussis vaccines during the last decades, pertussis has remained an endemic disease with frequent epidemic outbreaks. Currently two types of vaccines are used: whole-cell vaccines (WCVs) and recently developed acellular vaccines (ACVs). The long-term aim of our studies is to assess the effect of different vaccination policies on the population structure of Bordetella pertussis and ultimately on the disease burden in Europe. In the present study, a total of 102 B. pertussis isolates from the period 1998 to 2001 from five European countries (Finland, Sweden, Germany, The Netherlands, and France) were characterized. The isolates were analyzed by typing based on variable number of tandem repeats (VNTR); by sequencing of polymorphic genes encoding the surface proteins pertussis toxin S1 and S3 subunits (ptxA and ptxC), pertactin (prn), and tracheal colonization factor (tcfA); and by fimbrial serotyping. The results reveal a relationship between geographic location and VNTR types, the frequency of the ptxC alleles, and serotypes. We have not observed a relationship between the strain characteristics we studied and vaccination programs. Our results provide a baseline which can be used to reveal changes in the B. pertussis population in Europe in the coming years.

show abstract

Randomised controlled trial of two-component, three-component, and five-component acellular pertussis vaccines compared with whole-cell pertussis vaccine

Cited by 295 publications

References 21 publications

Characterization of co-purified acellular pertussis vaccines

Characterization of co-purified acellular pertussis vaccines

The seroepidemiology of Bordetella pertussis infection in Western Europe

Analysis of Bordetella pertussis Populations in European Countries with Different Vaccination Policies

Contact Info

Product

Resources

About